Literature DB >> 27801994

Clinical evaluation of three-dimensional late enhancement MRI.

Konstantinos Bratis1, Markus Henningsson1, Chrisanthos Grigoratos2, Matteo Dell' Omodarme3, Konstantinos Chasapides4, Rene Botnar1, Eike Nagel5.   

Abstract

PURPOSE: To assess the diagnostic value of three-dimensional late enhancement (3D-LGE) for the detection of myocardial necrosis in a routine clinical setting. 3D-LGE has been proposed as a novel magnetic resonance (MR) technique for the accurate detection of myocardial scar in both the ventricles and atria. Its performance in clinical practice has been poorly examined.
MATERIALS AND METHODS: Fifty-seven patients referred for cardiac MR examination including scar imaging were prospectively enrolled. Gadolinium enhanced single breathhold 3D T1-weighted gradient-echo inversion recovery sequence and a conventional 2D-LGE sequence were performed using a 1.5 Tesla clinical MR imaging system. The presence, pattern and transmurality of LGE, diagnostic accuracy and level of diagnostic confidence as well as image quality (median quality, mean LGE signal intensity, sharpness, virtual scan time) were graded on a 4-point scale.
RESULTS: Interpretable images were obtained in 52/57 2D-LGE and in 47/57 3D high-resolution exams. LGE was detected in 10 patients with ischemic pattern, 9 with nonischemic pattern, while it was absent in 28, resulting in a total of 47 complete datasets. The detection of global and segmental LGE as well as its transmural extent were similar for both techniques (P = 0.65, P = 0.305, and P = 0.15, respectively). Image quality (median quality, LGE/ myocardial and LGE/ blood pool sharpness) was similar for both techniques (P = 0.740, P = 0.34, and P = 1.00, respectively), but LGE signal intensity was higher with 2D (P = 0.020).
CONCLUSION: 3D-LGE diagnostic and quality scores were comparable to 2D-LGE in a routine clinical setting. Further technical refinement is required for 3D LGE to offer a reliable alternative for high quality scar imaging. LEVEL OF EVIDENCE: 2 Technical Efficacy: Stage 2 J. MAGN. RESON. IMAGING 2017;45:1675-1683.
© 2016 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  2D; 3D; cardiac magnetic resonance; late gadolinium enhancement

Mesh:

Substances:

Year:  2016        PMID: 27801994     DOI: 10.1002/jmri.25512

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  5 in total

1.  3D Dixon water-fat LGE imaging with image navigator and compressed sensing in cardiac MRI.

Authors:  Martin Georg Zeilinger; Marco Wiesmüller; Christoph Forman; Michaela Schmidt; Camila Munoz; Davide Piccini; Karl-Philipp Kunze; Radhouene Neji; René Michael Botnar; Claudia Prieto; Michael Uder; Matthias May; Wolfgang Wuest
Journal:  Eur Radiol       Date:  2020-12-02       Impact factor: 5.315

Review 2.  Myocardial Architecture, Mechanics, and Fibrosis in Congenital Heart Disease.

Authors:  Sarah Ghonim; Inga Voges; Peter D Gatehouse; Jennifer Keegan; Michael A Gatzoulis; Philip J Kilner; Sonya V Babu-Narayan
Journal:  Front Cardiovasc Med       Date:  2017-05-23

3.  Fat-suppressed gadolinium-enhanced isotropic high-resolution 3D-GRE-T1WI for predicting small node metastases in patients with rectal cancer.

Authors:  Yan Chen; Xinyue Yang; Ziqiang Wen; Baolan Lu; Xiaojuan Xiao; Bingqi Shen; Shenping Yu
Journal:  Cancer Imaging       Date:  2018-05-21       Impact factor: 3.909

Review 4.  Whole-Heart High-Resolution Late Gadolinium Enhancement: Techniques and Clinical Applications.

Authors:  Solenn Toupin; Théo Pezel; Aurélien Bustin; Hubert Cochet
Journal:  J Magn Reson Imaging       Date:  2021-06-21       Impact factor: 5.119

5.  'Image-navigated 3-dimensional late gadolinium enhancement cardiovascular magnetic resonance imaging: feasibility and initial clinical results'.

Authors:  Konstantinos Bratis; Markus Henningsson; Chrysanthos Grigoratos; Matteo Dell'Omodarme; Konstantinos Chasapides; Rene Botnar; Eike Nagel
Journal:  J Cardiovasc Magn Reson       Date:  2017-12-04       Impact factor: 5.364

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.